Penumbra (PEN) positioned for share gains in stroke market - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $335.00 price target on Penumbra (NYSE: PEN), saying the stroke ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
